BiotechTube

Ecallantide + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Blood Loss, Surgical

Conditions

Blood Loss, Surgical

Trial Timeline

May 1, 2007 → Aug 1, 2008

NCT ID
NCT00448864

About Ecallantide + Placebo

Ecallantide + Placebo is a phase 2 stage product being developed by Merck for Blood Loss, Surgical. The current trial status is terminated. This product is registered under clinical trial identifier NCT00448864. Target conditions include Blood Loss, Surgical.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT00816023Phase 2Completed
NCT00448864Phase 2Terminated

Competing Products

20 competing products in Blood Loss, Surgical

See all competitors
ProductCompanyStageHype Score
micafungin + voriconazoleAstellas PharmaApproved
85
CefiderocolShionogiPhase 2
52
Bunazosin + Doxazosin + ValsartinEisaiApproved
85
PegfilgrastimKyowa KirinPhase 2
52
epoetin alfaJohnson & JohnsonPhase 2/3
65
epoetin alfaJohnson & JohnsonPhase 2/3
65
epoetin alfaJohnson & JohnsonPhase 2
52
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
77
AZD6140 + PlaceboAstraZenecaPhase 1
33
NKTR-118 + moxifloxacin + PlaceboAstraZenecaPhase 1
33
MEDI-551AstraZenecaPhase 1
33
Ecallantide + Cyklokapron(R)MerckPhase 2
52
DaptomycinMerckPhase 2
52
ecallantide + placeboMerckPhase 2
52
MK0859MerckPhase 1
33
HSC835NovartisPhase 2
52
AliskirenNovartisApproved
85
Aliskiren and HCTZNovartisApproved
85
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo AmlodipineNovartisPhase 2
52
Darbepoetin alfaAmgenPhase 1/2
40

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85